Compound ID | 131
Class: Glycopeptide
Spectrum of activity: | Gram-positive |
Details of activity: | MRSA (methicillin resistant Staphylococcus aureus) and VRE (vancomycin resistant Enterococcus sp.) |
Propensity to select resistant mutants: | Yes |
Institute where first reported: | Cooper Group, University of Queensland, Australia |
Year first mentioned: | unknown |
Highest developmental phase: | Preclinical |
Development status: | Experimental |